Clinical trials have demonstrated that Kyprolis can improve progression-free survival in patients with multiple myeloma. When combined with other agents like lenalidomide and dexamethasone, it has shown significant efficacy, extending the time patients remain free of disease progression. However, individual responses can vary, and factors such as previous treatment history and overall health can influence outcomes.